N/A N=54 Cognitive Behavior Therapy (CBT) and Mirror Training for Phantom Limb Pain
Phantom Limb
Primary: Phantom Limb Pain Questionnaire — 6.22; 5.71; 6.67; 4.86 units on a scale — p=.322
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy
Radiation Toxicity · Recurrent Breast Cancer · Stage I Breast Cancer
Primary: Acute and Grade 2 or Higher Radiation-related Skin Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 — 38; 38 percentage of…
N/A N=130 Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
Prostatic Neoplasms
Primary: Number of Prostate Cancer Diagnoses in MRI and no MRI Groups — 34; 34 participants
N/A N=48 Amplitude and Rate of Intrinsic Feedback During Treadmill Training for Parkinson's Disease
Parkinson's Disease · Treadmill
Primary: Motor Section of the Unified Parkinson's Disease Rating Scale (UPDRS-III) — 23.35; 22.96; 22.46; 18.81 units on a scale (0-4)
Phase 3 N=295 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Estrogen Receptor Positive · HER2 Positive Breast Carcinoma · HER2/Neu Negative
Primary: Progression-free Survival (PFS) — 4.7; 3.8 months — p=0.37
N/A N=48 Topcon 3D OCT-1000 Optical Coherence Tomography System
Retinal Disease · Glaucoma
Primary: Precision and Agreement Between the Topcon 3D OCT 1000 and the Identified Predicate Device — 235.0; 236.1; NA; 236.0 µm
Phase 4 N=52 Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Glaucoma
Primary: Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma — 9; 12 participants
Phase 3 N=302 A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
Opioid-Induced Constipation (OIC)
Primary: Incidence of Patients Experiencing at Least One Adverse Event (AE) — 32; 40; 33 Participants
Phase 2 N=33 Sodium Nitrite to Treat Arterial Aging
Vascular Aging
Primary: Baseline and Week 10 Flow-Mediated Dilation — 3.120; 4.307; 3.118; 3.740 %Change
Phase 3 N=20 Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg
Acute Uncomplicated Falciparum Malaria
Primary: Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate — 16 number of participants
Phase 2 N=6 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
GBM · Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab. — 6…
Phase 2 N=45 Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia
Dental Anesthesia Efficacy
Primary: Pulpal Anesthesia — 25; 14 participants
Phase 3 N=86 Role of Soy Supplementation in Prostate Cancer Development
Prostate Neoplasm
Primary: Effect of Soy Isoflavones on Serum Testosterone Levels. — 376; 405 ng/ml
N/A N=25 Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
N/A N=41 Decision Support Workshop for Breast Reconstruction
Breast Cancer
Primary: Decision Self-efficacy Scale — 5.7; 5.1 units on a scale